- Home
- OMC vs ROIV Comparison
OMC vs ROIV Comparison
Compare OMC & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OMC | ROIV |
|---|---|---|
| Founded | 1944 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.4B | 20.7B |
| IPO Year | 1994 | 2021 |
Fundamental Metrics
Financial Performance| Metric | OMC | ROIV |
|---|---|---|
| Price | $73.94 | $26.53 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 8 |
| Target Price | ★ $98.71 | $27.56 |
| AVG Volume (30 Days) | 4.0M | ★ 4.4M |
| Earning Date | 04-14-2026 | 02-06-2026 |
| Dividend Yield | ★ 4.25% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $17,271,900,000.00 | $29,053,000.00 |
| Revenue This Year | $44.95 | N/A |
| Revenue Next Year | $1.05 | $594.84 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 10.09 | N/A |
| 52 Week Low | $66.33 | $8.73 |
| 52 Week High | $87.17 | $30.33 |
Technical Indicators
Market Signals| Indicator | OMC | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 37.52 | 42.52 |
| Support Level | $70.49 | $20.46 |
| Resistance Level | $74.55 | $27.94 |
| Average True Range (ATR) | 2.32 | 0.88 |
| MACD | -0.72 | -0.38 |
| Stochastic Oscillator | 4.80 | 1.04 |
Price Performance
Historical ComparisonAbout OMC Omnicom Group Inc.
Omnicom is a holding company that owns several advertising agencies and related firms. It provides traditional and digital advertising services that include creative design, market research, data analytics, ad placement, and public relations. The firm operates globally, providing services in more than 70 countries; it generates more than one half of its revenue in North America and nearly 30% in Europe.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.